Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:SAVANASDAQ:STTKNASDAQ:TTPHNYSE:VHAQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSAVACassava Sciences$1.94+2.6%$1.89$1.15▼$42.20$91.30M-1.993.02 million shs483,223 shsSTTKShattuck Labs$1.04+2.5%$0.98$0.69▼$4.99$48.38M1.72342,758 shs96,036 shsTTPHTetraphase Pharmaceuticals$2.20$2.20$0.56▼$8.60$15.98M2.33932,542 shs282,689 shsVHAQViveon Health Acquisition$11.00$11.00$0.00▼$12.48$62.26M-0.112 shs99 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSAVACassava Sciences+2.65%-6.28%-8.06%+10.86%-90.20%STTKShattuck Labs+2.48%+6.45%-4.17%-12.29%-73.83%TTPHTetraphase Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VHAQViveon Health Acquisition0.00%0.00%0.00%0.00%+10.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationSAVACassava Sciences4.0228 of 5 stars3.33.00.04.71.10.81.3STTKShattuck Labs2.1676 of 5 stars3.42.00.00.00.61.71.3TTPHTetraphase PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVHAQViveon Health AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSAVACassava Sciences 2.50Moderate Buy$54.502,709.28% UpsideSTTKShattuck Labs 2.83Moderate Buy$7.50624.64% UpsideTTPHTetraphase Pharmaceuticals 0.00N/AN/AN/AVHAQViveon Health Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TTPH, SAVA, STTK, and VHAQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/27/2025STTKShattuck LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/25/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSAVACassava SciencesN/AN/AN/AN/A$3.03 per shareN/ASTTKShattuck Labs$5.72M8.67N/AN/A$1.67 per share0.62TTPHTetraphase Pharmaceuticals$7.38M2.17N/AN/A$6.68 per share0.33VHAQViveon Health AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSAVACassava Sciences-$24.34M-$1.50N/AN/AN/AN/A-87.72%-72.05%8/6/2025 (Estimated)STTKShattuck Labs-$75.41M-$1.39N/AN/AN/A-1,156.46%-79.69%-69.13%7/30/2025 (Estimated)TTPHTetraphase Pharmaceuticals-$70.08M-$22.85N/AN/AN/A-798.18%-210.86%-121.73%N/AVHAQViveon Health Acquisition-$610KN/A0.00∞N/AN/AN/AN/AN/ALatest TTPH, SAVA, STTK, and VHAQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025SAVACassava SciencesN/A-$0.48N/A-$0.48N/AN/A5/1/2025Q1 2025STTKShattuck Labs-$0.29-$0.27+$0.02-$0.27N/AN/A3/27/2025Q4 2024STTKShattuck Labs-$0.38-$0.37+$0.01-$0.37$1.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthSAVACassava SciencesN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ATTPHTetraphase PharmaceuticalsN/AN/AN/AN/AN/AVHAQViveon Health AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioSAVACassava SciencesN/A9.089.08STTKShattuck LabsN/A9.089.08TTPHTetraphase Pharmaceuticals0.063.663.56VHAQViveon Health AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSAVACassava Sciences38.05%STTKShattuck Labs58.74%TTPHTetraphase Pharmaceuticals42.29%VHAQViveon Health Acquisition22.14%Insider OwnershipCompanyInsider OwnershipSAVACassava Sciences12.20%STTKShattuck Labs12.00%TTPHTetraphase Pharmaceuticals5.70%VHAQViveon Health Acquisition75.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableSAVACassava Sciences3048.31 million42.41 millionOptionableSTTKShattuck Labs10047.90 million42.15 millionOptionableTTPHTetraphase Pharmaceuticals1197.26 millionN/AOptionableVHAQViveon Health Acquisition25.66 million1.40 millionNot OptionableTTPH, SAVA, STTK, and VHAQ HeadlinesRecent News About These CompaniesViveon Health Acquisition CorpNovember 21, 2024 | investing.comClearday, Inc. (CLRD)September 6, 2024 | finance.yahoo.comClearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success - UpdatedMay 3, 2024 | finance.yahoo.comClearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future SuccessMay 2, 2024 | finance.yahoo.comViveon Health Acquisition Corp.: Viveon Healthcare Acquisition Corp. Confirms Commitment To Proceed With Business Combination ProcessFebruary 28, 2024 | finanznachrichten.deVIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESSFebruary 27, 2024 | globenewswire.comNYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ)February 21, 2024 | finance.yahoo.comViveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSEDecember 27, 2023 | finance.yahoo.comNYSE American to Commence Delisting Proceedings Against Viveon Health Acquisition Corp. (VHAQ)December 22, 2023 | tmcnet.comSan Antonio, Texas Clearday (CLRD-OTCQX) is proud to honor our US Veterans through the Company’s Clearday Club in San Antonio, Texas.November 13, 2023 | finance.yahoo.comNYSE American to Commence Delisting Proceedings with Respect to the Warrants of Viveon Health Acquisition Corp. (VHAQ.WS)October 24, 2023 | finance.yahoo.comVHAQ-R Viveon Health Acquisition Corp.September 23, 2023 | seekingalpha.comViveon Health Acquisition Received Audit Opinion With Going Concern ExplanationSeptember 15, 2023 | marketwatch.comVIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATIONSeptember 15, 2023 | finance.yahoo.comViveon Healthcare Increases Consideration Offered to Clearday ShareholdersSeptember 5, 2023 | finance.yahoo.comSPAC Viveon ups merger consideration for Clearday to $500MAugust 29, 2023 | msn.comViveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger AgreementAugust 29, 2023 | finance.yahoo.comVIVEON HEALTH ACQUISITION CORP. RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-K FILINGApril 25, 2023 | finance.yahoo.comViveon Health Acquisition Corp. (VHAQ-RT)April 18, 2023 | finance.yahoo.com(Updated) Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to MarketApril 12, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTTPH, SAVA, STTK, and VHAQ Company DescriptionsCassava Sciences NASDAQ:SAVA$1.94 +0.05 (+2.65%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.92 -0.01 (-0.77%) As of 06/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Shattuck Labs NASDAQ:STTK$1.03 +0.03 (+2.48%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.03 0.00 (0.00%) As of 06/24/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.Tetraphase Pharmaceuticals NASDAQ:TTPHTetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.Viveon Health Acquisition NYSE:VHAQ$11.00 0.00 (0.00%) As of 01/30/2025Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
